Rilutek (riluzole), the first drug approved for amyotrophic lateral sclerosis
Aventis is now marketing Rilutek (riluzole), the first drug approved for amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease).
ALS is a progressive, degenerative nerve disease...leading to muscle weakness, paralysis, and eventually death.
ALS is thought to be caused by excess glutamate, the primary excitatory neurotransmitter. Too much glutamate damages the nerves.